Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cost of Revenue
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cost of Revenue
-¥4.8B
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-34%
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥39.6B
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-63%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥99.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
See Also
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cost of Revenue?
Cost of Revenue
-992.7m
CNY
Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cost of Revenue amounts to -992.7m CNY.
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-29%
Over the last year, the Cost of Revenue growth was 17%. The average annual Cost of Revenue growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been -28% over the past three years , -29% over the past five years .